The FDA is expected to review vaccinations for children aged 6 months and older on 15 June.
Pfizer-BioNTech has submitted data to the FDA for approval of a three-dose primary series for children aged 6 months to 4 years old.
Moderna's two-dose primary series will be assessed for children 6 months to 5 years old.
Currently, children aged 5 and older can receive Pfizer-BioNTech's COVID-19 vaccine.